Loading data for ENVB — first visit, this takes a few seconds.
Enveric Biosciences, Inc.
1.48 +0.04 (2.78%)
1.38 -2.52%
- Capitalización de mercado
- $6.36M
- Volumen
- 104K
Enveric Biosciences, Inc. (ENVB): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$2,03 | +$0,73 | +98.94% |
Métricas
- Precio de compra
- 1.08
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -12.1M
- 1.11
- -12.18
- n/a
- -1.01
- P/B (TTM)
- 0.69
- P/S (TTM)
- n/a
- Fecha de resultados
- n/a
- Precio de venta
- 1.81
- Volumen
- 104,183
- Volumen medio (20D)
- 120,341
- Abierto
- 1.48
- Anterior Cerrar
- 1.44
- Rango del día
- 1.41 - 1.54
- Rango de 52 semanas
- 1.17 - 13.25
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- Apr 23, 2008
Acerca de Enveric Biosciences, Inc.
Ver perfil →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Industria Biotechnology
Sector Healthcare
IPO Fecha May 4, 2015
Empleados 5
Bolsa de Valores NasdaqCM
Símbolo bursátil ENVB
Sitio web https://www.enveric.com